A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This clinical trial is evaluating a drug called AC176 in participants with metastatic
castration resistant prostate cancer (mCRPC) who have progressed on at least two prior
systemic therapies.
The main goals of this study are to:
- Find the recommended dose of AC176 that can be given safely to participants alone
- Learn more about the side effects of AC176
- Learn more about pharmacokinetics of AC176
- Evaluate the preliminary anti-tumor activity of AC176